Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer

Wu, Jianhong; Li, Guangxin; Wang, Zeyou; Yao, Yongliang; Chen, Rui; Pu, Xia; Wang, Jianjun

doi:10.1155/2015/435656

Cited by 81 publications

(66 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is thus not surprising that a significant number of miRNAs listed in this review have been also identified in the blood of patients suffering from unrelated pathologies (e.g. ; the circulating level of miR-21 is altered both in patients suffering from various cancers [62–64] and from obesity and/or T2DM [26,27,30,39]). As shown on Supplementary Table 6, 112 KEGG pathways were predicted to be collectively targeted by the 119 miRNAs commonly identified in the human blood [61].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Value of Cell-free Circulating Micrornas for Obesity and Type 2 Diabetes: A Meta-analysis

Villard¹,

Marchand²

2015

J Mol Biomark Diagn

109

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is the most common metabolic disorder worldwide. Because of population aging and increasing trends toward obesity and sedentary lifestyles, the number of affected individuals is increasing at worrisome rates. While both environmental and genetic factors are known to contribute to the development of T2DM, continuous research is needed to identify specific biomarkers that could aid both in prevention of the disease and development of newer therapeutic options. Circulating miRNAs are considered as potential biomarkers because they are stable and resistant to degradation by blood RNAses and are modified under different pathophysiological conditions. In this study we carried out a systematic electronic search on PubMed to retrieve all articles that have investigated circulating miRNAs for diagnosing obesity andT2DM in human. We also included lifestyle intervention studies known to be highly effective in delaying onset of diabetes, and studies analyzing the effect of bariatric surgery and anti-diabetic treatment. A total of 26 studies were enrolled in the global meta-analysis. Candidate miRNAs were defined as those reported in at least 2 studies with same direction of differential expression. Ten miRNAs altered in blood of patients suffering fromT2DM were identified (increased: miR-320a, miR-142-3p, miR-222, miR-29a, miR-27a, miR-375; decreased: miR-197, miR-20b, miR-17, miR-652) and 7 miRNAs in blood of obese subjects were identified (increased: miR-142-3p, miR-140-5p, miR-222; decreased:miR-21-5p, miR-221-3p, miR-125-5p, mir-103-5p). Both obese and T2DM patients had elevated concentrations of miR-142-3p and miR-222. MiRNAs target genes were predicted and their cellular functions are discussed in relation with the pathologies. Although a significant number of studies were taken into account in this review, we found a strong discrepancy between miRNA detection and quantification indicating that many of pre-analytical variables have yet to be normalized. Pre-analytical and analytical challenges are also discussed.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic Value of Cell-free Circulating Micrornas for Obesity and Type 2 Diabetes: A Meta-analysis

Villard¹,

Marchand²

2015

J Mol Biomark Diagn

109

View full text Add to dashboard Cite

show abstract

“…Still, future validation is needed for the above studies in order to demonstrate that AMOs can function as therapeutic agents against gastric cancer, it is thus important to have future functional studies on miR-21 and its regulatory elements/regulators in relation to gastric carcinomas. Recently, identification of circulating microRNAs in gastric cancer progression and treatment is an important approach in gastric cancer research [3,29]. Circulating miR-21 expression is also very important marker for prognostic tool for gastric carcinoma and miR-21 could be a prognostic biomarker for patients.…”

Section: Future Perspectives and Clinical Impactsmentioning

confidence: 99%

“…Cancer antigen 199 (CA199) and carcinoembryonic antigen (CEA) are two old common tumour diagnostic markers; however, their specificity and sensitivity are too low for gastric cancer diagnosis. Therefore, a good biomarker of screening for gastric cancer is urgently needed [3]. Currently, the prognosis of advanced gastric cancer remains poor since safe and effective adjuvant therapy options are limited.…”

Section: Introductionmentioning

confidence: 99%

“…Significantly, frequent miR-21 upregulation in gastric cancer suggests that it could also serve as a potential biomarkers for the diagnosis of gastric cancer [1]. Recently, several promising serum or plasma miRNA biomarkers for gastric cancer detection have been identified [12,23] and the plasma levels of miR-21 were significantly elevated in gastric cancer patients, thus it can be used as noninvasive biomarker in gastric cancer [3,24], but there is no report on other biological samples, like urine and faeces. Intrestingly, miR-21 is the most commonly overexpressed oncogenic miRNA, it may also serve as a potential biomarker for lymph node metastasis in gastric cancer [25].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Significance of microRNA 21 in gastric cancer

Sekar

Ravindran

Thirugnanasambantham

et al. 2016

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

“…Nanobiosensor development is particularly relevant for such miRNAs, whose aberrant expression has been shown to correlate with the pathogenesis and progression of several diseases including cancer [6,7]. , in particular, is largely studied since is overexpressed in a variety of solid [8,9] and hematological tumors [10,11]. For these reasons, miR-21 was selected as a microRNA prototype in this study.…”

Section: Introductionmentioning

confidence: 99%

Enhancing miRNAs Capture on Polydimethylsiloxane Surface with Nanostructuration

Guida¹,

Savio²,

Potrich³

et al. 2017

J Nanomed Nanotechnol

View full text Add to dashboard Cite

IntroductionIn the last years, predictive and preventive medicine took advantage on the novel discoveries in nano-diagnostics and smart therapies, mainly based on the specific identification of molecular biomarkers, such as nucleic acids (DNA, miRNA) and proteins. The possibility to detect low amount of biomarkers directly in biological fluids gives a great advantage in the early diagnosis and therapy of malignant diseases, which have high social impact. In fact, a correlation between degenerative, contagious, or inflammatory illnesses with the presence of specific biomarkers like miRNAs is now well established [1][2][3][4][5]. However, this remains a challenging task since in each biological sample several different biomolecular species co-exist, and moreover it is very hard to treat them in order to achieve the degree of purity and concentration required for a quantitative, specific, and reliable identification. To overcome these obstacles, several nanotechnologybased systems are being developed and tested for miRNAs detection. Nanobiosensor development is particularly relevant for such miRNAs, whose aberrant expression has been shown to correlate with the pathogenesis and progression of several diseases including cancer [6,7]. , in particular, is largely studied since is overexpressed in a variety of solid [8,9] and hematological tumors [10,11]. For these reasons, miR-21 was selected as a microRNA prototype in this study.Recently, it has been proposed that nanotechnology-based approaches [12][13][14] alternative to conventional methods [15][16][17][18][19] for miRNA detection and quantification can be developed using innovative biosensors made of Polydimetylsiloxane (PDMS) [20][21][22]. PDMS is known to have numerous advantages, supporting its development as a useful platform for biosensor and biomedical applications [20,[23][24][25]. Particularly, the attractiveness of such polymer lies in the fact that its chemical and physical properties and also the surface topography can be modulated [26]. These features combined with the manufacturing of biomolecule-specific topographies contribute to the improvement of PDMS performance in terms of sensitivity and efficiency. Recently, the fabrication of PDMS-based devices has introduced significant advances in several analytical techniques in terms of sensitivity, time consuming, and sample volume. Since PDMS material revealed characteristic properties and reliability, PDMS-nanotechnology has therefore gained great attention in developing new generation of research tools. However, both traditional and technology-based approaches have yet limitations mainly related to sample processing, purification, separation and enrichment of the small RNA fraction [12,27]. In fact, advanced biosensors still require specific conjugation steps [28] and expensive equipment which need to be overcome before they can have a real clinical application.PDMS nanostructures manufacturing may be useful to enhance the efficient purification of miRNA circulating bio-markers present at low Abstrac...

show abstract

Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer

Cited by 81 publications

References 42 publications

Diagnostic Value of Cell-free Circulating Micrornas for Obesity and Type 2 Diabetes: A Meta-analysis

Diagnostic Value of Cell-free Circulating Micrornas for Obesity and Type 2 Diabetes: A Meta-analysis

Significance of microRNA 21 in gastric cancer

Enhancing miRNAs Capture on Polydimethylsiloxane Surface with Nanostructuration

Contact Info

Product

Resources

About